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ABSTRACT
The 67 kDa laminin receptor (67LR) is a non-integrin receptor for laminin (LM) 
that derives from a 37 kDa precursor (37LRP). 67LR expression is increased in 
neoplastic cells and correlates with an enhanced invasive and metastatic potential.
We used structure-based virtual screening (SB-VS) to search for 67LR inhibitory 
small molecules, by focusing on a 37LRP sequence, the peptide G, able to specifically 
bind LM. Forty-six compounds were identified and tested on HEK-293 cells transfected 
with 37LRP/67LR (LR-293 cells). One compound, NSC47924, selectively inhibited LR-
293 cell adhesion to LM with IC50 and Ki values of 19.35 and 2.45 μmol/L.
NSC47924 engaged residues W176 and L173 of peptide G, critical for specific 
LM binding. Indeed, NSC47924 inhibited in vitro binding of recombinant 37LRP to 
both LM and its YIGSR fragment. NSC47924 also impaired LR-293 cell migration to 
LM and cell invasion.
A subsequent hierarchical similarity search with NSC47924 led to the 
identification of additional four compounds inhibiting LR-293 cell binding to LM: 
NSC47923, NSC48478, NSC48861, and NSC48869, with IC50 values of 1.99, 1.76, 3.4, 
and 4.0 μmol/L, respectively, and able to block in vitro cancer cell invasion.
These compounds are promising scaffolds for future drug design and discovery 
efforts in cancer progression.
INTRODUCTION
The 67 kDa laminin receptor (67LR) was originally 
identified as a non-integrin cell surface receptor for LM 
[1], the major component of basement membranes [2]. 
Interactions between 67LR and LM play a major role in 
mediating cell adhesion [3], migration [4], proliferation 
and survival [5].
67LR derives from homo- [6] or hetero- [7] dimeri-
zation of a 37 kDa cytosolic precursor (37LRP) [8], most 
probably by fatty acid acylation. 37LRP is mostly found 
in the cytosol [9] and nucleus [10] where it is involved 
in translational processes and maintenance of nuclear 
structures, respectively. 67LR is localized at the cell 
surface [11] and it not only serves as a receptor for LM 
but also acts as a receptor for elastin [12], carbohydrates 
[13] and the cellular prion protein [14].
67LR binds LM through different binding domains: 
a palindromic sequence known as peptide G [11, 15], a 
predicted helical domain corresponding to 37LRP residues 
205–229, and TEDWS-containing C-terminal repeats 
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[13]. 67LR is co-expressed and can physically interact 
with the α6 integrin chain [16]. LM conformation changes 
upon binding 67LR, thus interacting more efficiently with 
integrins [17] and becoming more sensitive to the action 
of proteolytic enzymes [18], with the release of motility 
fragments [19].
67LR expression is increased in neoplastic cells 
as compared to their normal counterparts and directly 
correlates with an enhanced invasive and metastatic 
potential [20], mediated by high-affinity interactions 
between 67LR and LM [21].
Cell adhesion to the basement membrane allows 
tumor cells to secrete proteolytic enzymes, i.e. type 
IV collagenase, able to degrade components of the 
extracellular matrix (ECM). Degradation of these 
components, in turn, induces invasion of the basement 
membrane, enabling cancerous cells to migrate and form 
metastasis. Thus, 67LR overexpression is a molecular 
marker of aggressiveness in cancers of many tissues, 
including breast, lung, ovary, prostate and also in 
leukaemia and lymphomas [22–24].
The correlation between 37LRP/67LR levels 
and tumor aggressiveness recommends the receptor as 
a new promising target for cancer treatment. This is 
supported by in vivo studies showing that high 67LR 
levels result in tumor growth and proliferation [25, 
26]. Knockdown of 37LRP using siRNAs resulted in 
decreased cell survival suggesting that 37LRP/67LR 
could also enhance cell viability by blocking apoptosis 
[27]. Indeed, we recently demonstrated the structural 
and functional association of 67LR with the anti-
apoptotic protein PED/PEA-15 [28]. Furthermore, 
recent findings demonstrated that an anti-37LRP/67LR 
specific antibody significantly impeded angiogenesis, 
thus suggesting the receptor might also be involved in 
tumor angiogenesis [29].
However, an anti-37LRP/67LR specific antibody 
decreased the invasive potential of human fibrosarcoma cells 
[30], thus indicating that 67LR plays a critical role in tumor 
invasion and metastasis through its interaction with LM.
The 2.15 Å resolution crystal structure of the 
partial domain of human 67LR [31] provides an excellent 
platform for rational drug design. For these reasons, we 
used structure-based virtual screening (SB-VS) [32] of 
the National Cancer Institute (NCI) Diversity Set with 
nonredundant structures to identify small molecules 
targeting 67LR and able to disrupt cell binding to LM. SB-
VS, which uses computer-based methods for identifying 
promising compounds to bind to a target molecule of 
known structure, is a widely used method that has been 
shown to be successful in a variety of studies, although it 
also has many shortcomings [33].
Here, we describe the successful outcome of this 
search and the initial biological evaluation of the most 
promising compounds from this effort.
RESULTS
Identification of a druggable pocket within the 
human 67LR structure
Recently, the structure of the N-terminal of 37LRP 
(residues 1–220) has been solved by X-ray crystallography 
[31] with resolution of 2.15 Å (Protein Data Bank ID code 
3BCH) (Figure 1A). 37LRP was shown to have a globular 
structure comprising five α-helical and seven β-folded 
regions. This structure shows a high degree of similarity to 
ribosomal protein SA or p40 from prokaryotes and lower 
eukaryotes [9, 34]. Since 37LRP crystal structure begins at 
residue 9 (Q9; single-letter amino-acid code) and finishes 
at residue 205 (R205) (both indicated on the Figure 1A), it 
lacks almost all the C-terminal domain, not present in the 
Figure 1: Structure of human 37LRP. A. Structure of human 37LRP represented as a slate blue cartoon. The structure begins at 
residue Q9 and finishes at residue R205, lacking almost all the C-terminal LM-binding site, which starts at residue R205. Peptide G 
(residues 161–180) is shown in yellow. The surface loop (residues 187–205), which covers the palindromic sequence of peptide G, is 
shown in magenta. B. Structure of human 37LRP lacking of the surface loop. The palindromic sequence of peptide G (LMWWML) is 
circled in black. C. The 2265 Å2 putative LM binding pocket lying between αC and αE helices of 37LRP. Figures were produced using 
the coordinates from Protein Data Bank file 3BCH (35) and PyMOL (www.pymol.org).
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prokaryotic and lower eukaryotic ribosomal proteins [35], 
which starts at residue 205.
Among the different 67LR binding sites for LM, 
we focused on peptide G for the abundant clinical and 
experimental data indicating its critical role in tumor 
invasion and metastasis [11, 15, 17–21]. Peptide G 
(residues 161–180, IPCNNKGAHSVGLMWWMLAR) 
binds LM with high affinity (Kd = 51.8 nM) [11, 15, 
17]. Moreover, evolutionary studies suggested that the 
acquisition of the LM-binding capability of 67LR is linked 
to the palindromic sequence LMWWML contained within 
the peptide G [35]. Peptide G forms part of a β-strand 
(residues 160–162), an α-helix (residues 168–186) and a 
surface loop (residues 187–205), much of which is buried 
in the interior of the molecule. The only portion of it that 
is solvent-accessible includes residues 165–169.
The crystal structure of 37LRP reveals that the 
surface loop completely covers the palindromic sequence 
of peptide G, making it inaccessible to binding of LM 
(Figure 1A); thus, it has been postulated that considerable 
conformational changes are required to enable LM 
binding. Indeed, we found that loop 188–197 in the 
C-terminal region is highly flexible and undergoes a major 
change resulting in a conformational switch that partially 
solvent exposes the final part of peptide G [36].
Thus, with the aim of exposing the palindromic 
sequence (Figure 1B) involving protein-LM interactions, 
we truncated the surface loop of 37LRP (residues 187–205) 
from the available crystallographic structure. One cavity was 
intercepted in close proximity of the palindromic residue 
W176. This groove lies between two α helices (αC and αE) 
and covers a surface area of 2265 Å2 (Figure 1C). The site is 
predominantly hydrophobic in nature (L173, M174, M177, 
L178, A86, G172, A93, A179, G172, A168, F90, W175, 
W176) with a few H-bond donors and acceptors. This putative 
cavity, that we hypothesize to be involved in LM binding, was 
chosen for in silico targeting in a SB-VS approach.
Identification by SB-VS of small molecules 
directed to the peptide G cavity of 67LR
An in silico screening approach was undertaken to 
identify compounds from the NCI Diversity library with a 
potential to bind at the putative cavity on the peptide G of 
67LR and hamper LM binding. 3D structures of compounds 
from the NCI’s chemical libraries were downloaded from 
the NCI Developmental Therapeutics Program web site 
(http://dtp.nci.nih.gov/branches/dscb/repo_open. html/) 
and processed with LigPrep software to produce 2, 560 3D 
structures for the Diversity Set. Docking calculations were 
carried out by using the Glide software [37]. Then, Glide SP 
docked each chemical structure into the 67LR/LM binding 
site retaining the 10% of the top-scoring ligands. The 
resulting 188 compounds were then redocked and scored 
with Glide XP in order to estimate binding affinity and rank 
the ligands. The 188 ranked compounds were analyzed 
by visual inspection because it has broadly demonstrated 
that docking scoring functions are often more successful at 
predicting a binding pose than the actual binding affinity 
[38]. Finally, compounds were checked for readily sample 
availability from the compound provider, and 46 structurally 
diverse compounds (compounds 1-46 in Chart 1 of 
Supplementary Material: SB-VS selected small molecules 
directed to the peptide G cavity of 67LR) were requested 
and tested in a cell-based assay.
Human 37LRP cDNA transfection in HEK-293 
cells results in cell surface expression of the active 
receptor and increased cell adhesion to LM
As a model to mimic the effects of 67LR 
overexpression in cancer cells, HEK-293 cells were 
stably transfected with a human 37LRP cDNA fused at the 
C-terminal with a tag derived from phage T7 and a poly-
histidine stretch (LR-293 cells) or with an empty vector 
(V-293 cells).
37LRP expression was then evaluated by Western 
blot analysis, using an anti-37LRP/67LR polyclonal 
antibody and an anti-T7 tag monoclonal antibody, in 
V-293 and LR-293 cell lysates. LR-293 cells expressed 
both endogenous and transfected 37LRP (37LRP/T7tag), 
whereas V-293 cells expressed only endogenous 37LRP 
(Figure 2A).
To verify that transfected 37LRP was correctly 
processed into the mature form and over-expressed at 
the cell surface, flow cytometry analysis was performed 
on V-293 and LR-293 cells with the same polyclonal 
antibody. LR-293 cells showed increased 67LR surface 
expression in respect to V-293 cells (Figure 2B).
Finally, 67LR overexpressed on LR-293 cell surface 
was functionally active; indeed, LR-293 cell adhesion to 
LM was significantly increased, as compared to V-293 
cells, and such an increase was completely abrogated 
by cell pre-treatment with anti-37LRP/67LR polyclonal 
antibodies (Figure 2C).
Cell adhesion to LM of 67LR overexpressing 
cells is inhibited by SB-VS selected compounds
To identify potential molecules able to inhibit 
67LR binding to LM, LR-293 cells were subjected to 
adhesion experiments on LM-coated wells in the presence 
of the 46 initial hits, dissolved in DMSO and added at a 
concentration of 2×10–5 M; DMSO alone was used as a 
negative control.
Among the 46 candidates, only five compounds 
(Table 1) were able to inhibit LR-293 cell adhesion to LM 
(Figure 3A). Moreover, all these compounds satisfy the 
druglikeness rules defined by Qikprop (QikProp, version 
4.1, Schrödinger, LLC).
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NSC47924 is a specific inhibitor of cell 
binding to LM
To verify their specificity, the five active compounds 
were tested for the ability to inhibit LR-293 cell adhesion 
to LM, FN and VN. Only one compound selectively 
inhibited LR-293 cell adhesion to LM. This molecule, 
NSC47924 [1-((4-methoxyanilino)methyl)-2-naphthol], 
strongly and specifically decreased cell binding to LM 
without significantly affect cell adherence to FN and VN 
(Figure 3B). On the contrary, the other compounds also 
inhibited cell binding to VN and FN (not shown) and were 
withdrawn from the study for their lack of specificity.
NSC47924 inhibits cell binding to LM in a  
dose-dependent manner with a micromolar affinity
LR-293 cell adhesion to LM was also evaluated in 
the presence of decreasing concentration of NSC47924, 
in order to evaluate the dose-dependency of its inhibi tory 
activity. IC
50
 value was 19.35 μM, as calculated by non-
linear regression curves using the sigmoidal dose-response 
analysis of the GraphPad Prism software (Figure 3C). Ki of 
NSC47924 was 2.45 μM, as calculated by the Cheng and 
Prusoff Equation from EC
50
, using GraphPad Prism [39].
LR-293 cell adhesion to increasing concentrations 
of LM in the presence of NSC47924 at its IC
50
 was also 
evaluated. In the absence of inhibitors, LR-293 cell 
adhesion to LM showed a Kd of 14.5 nM, similar to 
that already reported for in vitro 67LR binding to LM 
[2 nM; ref. 40]; the addition of NSC47924, at its IC
50
, 
resulted in a significant loss of LR-293 cell binding to 
LM (Figure 3D).
NSC47924 specifically inhibits 67LR-mediated 
cell adhesion, migration and invasion
67LR mediates high affinity interaction between 
cells and LM, thus increasing cell migration and 
invasiveness in overexpressing cells [21, 22–24, 30]; 
therefore, it was investigated whether NSC47924 was 
able to specifically inhibit 67LR-mediated cell adhesion 
and migration to LM and basement membrane invasion in 
LR-293 cells, using V-293 cells as a control.
Figure 2: 37LRP cDNA transfection in HEK-293 cells results in cell surface expression of the mature receptor and 
increased cell adhesion to LM. A. HEK-293 cells were transfected with 37LRP cDNA fused at the C-terminal with a T7 tag and a 
poly-histidine stretch (37LRP/T7-tag), and named LR-293, or with the empty vector, V-293. Transfected cells were lysed and 50 μg of 
protein was analyzed by Western blot with 37LRP/67LR and T7-tag specific antibodies. B. Flow cytometric analysis of cell surface 67LR 
expression was evaluated by incubating V-293 and LR-293 cells with a polyclonal anti-67LR antibody or an isotype control. Fluorescence 
intensity values are reported. C. V-293 (■) and LR-293 (■) cells were plated on LM-coated wells in the presence of 20 μg/ml non immune 
immunoglobulins or anti-37LRP/67LR polyclonal antibodies. The attached cells were stained and the absorbance at 540 nm was measured. 
The values represent the mean ± SD of three experiments performed in triplicate. (*) p < 0.05, as determined by the Student’s t test.
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Table 1: Experimentally Determined % Cell adhesion Inhibition, XP Docking Scores, and 
Properties Predicted by QikProp from 46 Screened Compounds
Cpd Structure NCI 
number
MWa QP log 
Pb
QPlog 
Sc
QP 
P
Caco
d
QP log 
Khsae
Score 
(kcal/
mol)
% 
inhibition
13
 
47924 279.3 4.0 –4.3 3784 0.365 –5.90 78
20
 
84094 327.4 4.4 –5.2 1686 0.572 –4.74 13
30
 
17383 344.9 5.0 –5.1 596 0.943 –3.82 93
36
 
135900 352.4 5.7 –6.2 403 0.996 –4.89 37
(Continued )
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To this aim, in vitro adhesion and migration assays to 
LM as well as Matrigel invasion assays were performed, in 
the presence or in the absence of 20 μM NSC47924. 67LR 
overexpressing LR-293 cells showed increased adhesion 
to LM, migration toward LM and Matrigel invasion, as 
compared to V-293 cells (Figure 4A, 4B, 4C). NSC47924 
significantly inhibited LR-293 cell adhesion/migration to 
LM and invasion, as compared to vehicle treated cells; no 
significant effect was observed on V-293 cells (Figure 4A, 
4B, 4C). NSC373070, an inactive compound derived from 
the 46 initial hits (Chart 1 of Supplementary Material), 
was added as a negative control and was ineffective in 
inhibiting LR-293 cell adhesion/migration to LM and 
Matrigel invasion, as expected (Figure 4A, 4B, 4C).
Thus, a novel small molecule specifically inhibiting 
cell binding to LM and its functional effects in 67LR 
overexpressing cells was identified by SB-VS.
NSC47924 is a direct inhibitor of 37LRP/LM 
complex
To further demonstrate the specificity of 37LRP/67R 
as a target, the ability of NSC47924 to inhibit the binding 
to LM of human recombinant soluble 37LRP (r37LRP) 
was evaluated.
In order to demonstrate r37LRP ability to bind 
LM, serial dilution of purified His-tagged r37LRP was 
incubated on wells pre-coated with LM, and binding 
was detected by anti-His HRP. As a control for binding 
specificity, r37LRP binding to BSA-coated wells was 
also evaluated in parallel and the OD readings subtracted. 
r37LRP specifically bound to LM, albeit with a lower 
efficiency than 67LR overexpressing cells, showing a 
Kd of 1.9 μM (Figure 5A), similar to that reported for a 
truncated form of 37LRP [2.3 μM; ref. 41].
Then, NSC47924 ability to inhibit r37LRP binding 
to LM was evaluated. NSC47924 inhibited r37LRP 
binding to LM, showing a IC
50
 of 58.9 μM and a Ki of 35.5 
μM (not shown). Thus, NSC47924 is a specific inhibitor of 
37LRP/67LR direct binding to LM (Figure 5B).
The precise contact site on LM for 67LR have 
not been mapped yet. However, it is believed that the 
interaction involves a specific peptide from the β1 chain 
of laminin (YIGSR) [42]; the binding activity of this 
synthetic peptide is increased by an amide group at the 
C-terminal [3]. Moreover, YIGSR is able to displace 
peptide G from LM, thus blocking the peptide G-mediated 
increase in LM degradation [18–19]. For these reasons, 
we investigated whether NSC47924 was able to compete 
for r37LRP binding to YIGSR. NSC47924 significantly 
inhibited r37LRP binding to YIGSR (Figure 5C), leading 
us to hypothesize that our target sequence, peptide G, 
could be effectively addressed by NSC47924.
Docking experiments were performed to gain insight 
into the possible mechanisms of interaction between 
NSC47924 and peptide G of 37LRP. As shown in Figure 5D, 
the naphthol ring of the ligand is sandwiched between two 
α-helices (αC and αE) of 37LRP and held in place by a H-bond 
Cpd Structure NCI 
number
MWa QP log 
Pb
QPlog 
Sc
QP 
P
Caco
d
QP log 
Khsae
Score 
(kcal/
mol)
% 
inhibition
37
 
45382 439.9 2.0 –4.7 126 –0.225 –3.85 97
aMW, range 95% of drugs (130/725).
bPredicted octanol/water log P, range 95% of drugs (–2/6.5).
cPredicted aqueous solubility, S, in mol/L, range 95% of drugs (–6.5/0.5).
dPredicted Caco-2 cell permeability in nm/s, range 95% of drugs (<25 poor, >500 great).
ePredicted binding to human serum albumin, range 95% of drugs (–1.5/1.5).
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formed between the hydroxyl group of NSC47924 and the 
G172 CO backbone. The naphthol moiety also engages a 
network of hydrophobic contacts with F90, W175, A86, 
G172, W176, A93, A179 residues. In addition, the pendant 
p-methoxy phenyl ring makes hydrophobic interactions with 
the palindromic residues W176 and L173. The aromatic side 
chain of W176 establishes an aromatic π-stacking interaction 
with the p-methoxy phenyl ring, contributing to further 
stabilize the complex. The latter residues have been shown 
to be critical for specific binding of LM to 37LRP [35]. Close 
inspection of the NSC47924/37LRP complex also shows that 
the bulky p-metoxy group of the ligand makes van der Waals 
contacts with the side chain of K17.
Refinement of lead 67LR inhibitor NSC47924
Hierarchical screening is an efficient strategy that 
allows an initial broad search over a chemically and 
pharmacologically diverse set of compounds, followed by a 
focused search over a much larger database to find molecules 
related to potential lead compounds. A similarity search 
over the full NCI database with NSC47924 resulted in 108 
Figure 3: Five top-scoring molecules from SB-VS of a diversity library of small molecules inhibit LR-293 cell adhesion 
to LM; but, only one compound, NSC47924, shows specificity for LM. A. LR-293 cells were plated in LM-coated wells in the 
presence of SB-VS selected molecules, at a concentration of 20 μM, DMSO was used as negative control (■). The attached cells were stained 
and the absorbance at 540 nm was measured. The values represent the mean ± SD of three experiments performed in triplicate. (*) p < 0.05, 
as determined by the Student’s t test. Among the 46 small molecules tested, only five compounds were able to inhibit LR-293 cell binding 
to LM and are shown. B. LR-293 cell adhesion to LM, fibronectin (FN) and vitronectin (VN), in the presence of 20 μM NSC47924 (■) or 
DMSO, as a negative control (■). The attached cells were stained and the absorbance at 540 nm was measured. The values represent the mean 
± SD of three experiments performed in triplicate. (*) p < 0.05, as determined by the Student’s t test. NSC47924, specifically decreased LR-
293 cell binding to LM, without affecting cell adherence to FN and VN. C. LR-293 cells were plated on LM-coated wells in the presence of 
decreasing concentrations of NSC47924. The attached cells were stained and the absorbance at 540 nm was measured. The values represent 
the mean ± SD of three experiments performed in triplicate. NSC47924 inhibits LR-293 cell adhesion to LM in a dose dependent manner. D. 
LR-293 cells were plated for 1 hour on wells coated with increasing concentrations of LM in the presence of NSC47924 (▲), at its IC
50
, or 
DMSO (■) , as a vehicle control; attached cells were stained and the absorbance at 540 nm was measured. Values represent the mean ± SD of 
three experiments carried out in triplicate. The addition of NSC47924, at its Ic
50
, resulted in a significant loss of LR-293 cell binding to LM.
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compounds, which we docked to the putative cavity found 
in close proximity of 37LRP crystal structure and ranked 
according to predicted binding energy. The top 19 compounds 
based on a binding energy cutoff of –7 kcal/mol were selected 
for experimental testing (compounds 47–65 in Chart 2 of 
Supplementary Material: Refinement of lead 67LR inhibitor 
NSC47924).
The 19 top-ranked compounds identified in the 
similarity screen were tested at 20 μM concentration by in 
vitro cell adhesion assay to LM. Eight compounds were able 
to inhibit the adhesion of LR-293 cells to LM (Figure 6A), 
but only four of them, NSC47923 [1-(4-toluidinomethyl)-
2-naphthol], NSC48478 [1-((4-chloroa nilino)methyl)-
2-naphthol], NSC48861 [1-((((2-hydroxy-1-naphthyl)
methyl)-4-methylanilino)methyl)-2-naphthol] and 
NSC48869 [1-((((2-hydroxy-1-naphthyl)methyl)anilino)
methyl)-2-naphthol] (Table 2) selectively inhibited LR-293 
cell binding to LM without exerting a significant effect on 
cell binding to FN.
To also demonstrate the specificity for 67LR as 
a target, selected analogs were tested for their ability 
to inhibit the direct r37LRP binding to LM. NSC47923, 
NSC48478, NSC48861 and NSC48869 were active to 
the same extent as NSC47924, by in vitro binding assays 
(Figure 6C).
Interestingly, all active analogs showed 
IC
50
 values lower than NSC47924, when tested at 
decreasing concentrations on LR-293 cell adhesion 
assays (Table 2).
Modes of binding for the top five inhibitors  
of 67LR
The five micromolar drug-like inhibitors 
of 67LR that we have identified, all share a core 
1-(anilinomethyl)-2-naphthol scaffold, which is pre-
dicted to bind in the deep putative 37LRP binding cleft 
(Figure 7). The core scaffold, including the H-bonding 
interaction with the carbonyl backbone of G172, 
conserves many protein-ligand interactions previously 
described for NSC47924 (Figure 5D). The naphthol 
moiety preserves hydrophobic interactions with F90, 
W175, A86, G172, W176, A93, and A179 residues, 
whereas the p-substituted phenyl ring maintains 
hydrophobic and aromatic π-stacking interactions with 
the palindromic residues W176 and L173. However, 
the differences of the p-substituents account for a 
large difference in activity. NSC47924 is 9.7-fold and 
10.9-fold less active than NSC47923 and NSC48478, 
respectively. This suggests that the unfavourable steric 
interactions of the bulky methoxy group of NSC47924 
and the K17 side chain would be removed by the less 
sterically demanding methyl group (NSC47923) and 
chlorine atom (NSC48478). The additional 2-naphtol 
ring in both NSC48861 and NSC48869 establishes 
favorable hydrophobic contacts with residues G172, 
L173 and H169, allowing the exploration of a rather 
lipophilic region of 67LR. One can speculate that 
specific ligand interactions with this region of the 
Figure 4: NSC47924 specifically inhibits 67LR-mediated cell adhesion and migration to LM as well as ECM invasion. A. 
V-293 and LR-293 cells were plated on LM-coated wells in the presence of DMSO (□), as a vehicle control, 20 μM NSC47924 (■), or 
NSC373070 (■) as a negative control. The attached cells were stained and the absorbance at 540 nm was measured. The values represent the 
mean ± SD of three experiments performed in triplicate. (*) p < 0.05, as determined by the Student’s t test. B. V-293 and LR-293 cells were 
pre-incubated with DMSO (□), 20 μM NSC47924 (■), or NSC373070 (■) as a negative control, plated in Boyden chambers and allowed to 
migrate toward 50 μg/ml LM on filters coated with 10 μg/ml FN. The values are the mean ± SD of three experiments performed in triplicate. 
(*) p < 0.05, as determined by the Student’s t test. C. V-293 and LR-293 cells were preincubated with DMSO (□), 20 μM NSC47924 (■), 
or NSC373070 (■) as a negative control, plated in Boyden chambers and allowed to invade MatrigelTM. The values are the mean ± SD of 
three experiments performed in triplicate. (*) p < 0.05, as determined by the Student’s t test. NSC47924 inhibited LR-293 cell adhesion and 
migration to LM as well as Matrigel invasion without exerting any significant effect on vector transfected V-293 cells.
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binding site could increase the inhibitory potency of 
these two compounds at 67LR.
NSC47923, NSC48478, NSC48861 and 
NSC48869 inhibit tumor cell invasion
It has been widely reported that 67LR enhances 
cancer cell invasion and tumor metastasis by engaging 
LM and promoting ECM breakdown and the release of 
LM-derived motility fragments [18, 19].
Therefore, we sought to investigate whether 
selected compounds were able to inhibit the invasion 
through reconstituted basal membranes of highly invasive 
human fibrosarcoma HT1080 and human breast cancer 
MDAMB231 cell lines, constitutively expressing high 
67LR levels [30, 43].
All compounds strongly reduced Matrigel invasion, 
as compared with DMSO-treated cells (Figure 8A). 
Interestingly, selected compounds were still active at 
concentrations of 10 μM and 5 μM (Figure 8B), thus 
highlighting an increased in vivo activity, as compared to 
NSC47924 (Figure 4C), most likely due to their lower IC
50
 
(Table 2). NSC210423, an inactive analog derived from 
the 19 top-ranked compounds identified in the similarity 
screen (Chart 2 of Supplementary Material), was added 
as a negative control and was ineffective in inhibiting 
Matrigel invasion, as expected (Figure 8A, 8B).
Therefore, four newly identified small-molecule 
inhibitors of 67LR are able to block cancer cell invasion 
by targeting the direct 67LR binding to LM, at low 
micromolar concentrations.
DISCUSSION
Virtual screening (VS) has been successfully adopted 
as an attractive and complementary alternative to expedite 
and facilitate new lead compound identification for a specific 
biological target from large chemical libraries. Typically, 
VS encompasses a variety of computational techniques 
to prioritize compounds and it is fast and cost-effective 
Figure 5: Structural basis of 67LR inhibition by NSC47924. A. Increasing concentrations of purified human His-tagged 
recombinant 37LRP (r37LRP) were placed for 1 hour at 37°C on wells coated with 1 μg of LM. Bound r37LRP was revealed by anti- 
His-HRP and OPD staining; the absorbance at 490 nm was measured. r37LRP binding to BSA-coated wells was subtracted to obtain 
specific binding. Values represent the mean ± SD of three experiments carried out in triplicate; (*, P < 0.05), as determined by the Student’s t 
test. Human r37LRP binds to LM in a dose dependent manner. B. r37LRP was placed for 1 hour at 37°C on LM-coated wells in the presence 
of increasing concentrations of NSC47924 or DMSO (■), as a vehicle control. Bound r37LRP was revealed by anti-His-HRP and OPD 
staining; the absorbance at 490 nm was measured. r37LRP binding to BSA-coated wells was subtracted to obtain specific binding. Values 
represent the mean ± SD of three experiments carried out in triplicate; (*, P < 0.05), as determined by the Student’s t test. C. r37LRP was 
placed for 1 hour at 37°C on wells coated with 100 μg of YIGSR in the presence of increasing concentrations of NSC47924 or DMSO (■), 
as a vehicle control. Bound r37LRP was revealed by anti-His-HRP and OPD staining; the absorbance at 490 nm was measured. r37LRP 
binding to BSA-coated wells was subtracted to obtain specific binding. Values represent the mean ± SD of three experiments carried 
out in triplicate; (*, P < 0.05), as determined by the Student’s t test. D. Predicted binding mode of NSC47924. The most populated and 
lowest energy pose is shown for NSC47924 docked into the 37LRP crystal structure (slate blue cartoon). NSC47924 is shown in stick, 
with carbons in green, nitrogens in blue, and oxygen in red. H-bonds interactions are shown with dashed black lines. The protein residues 
are shown in yellow stick, while the palindromic key residues are displayed in blue sticks. Human recombinant 37LRP binds LM and is 
inhibited by NSC47924; NSC47924 engages many contacts with residues of 37LRP peptide G.
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in comparison to experimental high-throughput screening 
(HTS), thereby coming to the forefront in the modern drug 
discovery process [32]. There are two fundamental types 
of VS applications: structure-based virtual screening (SB-
VS) and ligand-based virtual screening (LB-VS). SB-VS 
uses the knowledge of the three-dimensional structure of 
the target to select candidates most likely to interact with 
the binding site of the target [33], while LB-VS employs 
information of the known active compounds as a search 
query to retrieve the potential actives from large chemical 
libraries [44]. The main advantages of SB-VS methods 
compared to LB-VS methods are the structural novelty 
of the hits discovered (not based on pre-existing, known 
ligands) and the possibility to model the binding mode of 
potential ligands within the binding site.
Availability of large number of protein targets in 
cancer offers an excellent opportunity to carry out VS. In 
cancer research, successful VS strategies to identify novel 
hits have been reported by various groups [45]. However, 
identified hits cannot directly enter into clinical trials, 
but may serve as starting point for further optimization. 
Therefore, the VS route of cancer drug discovery provides 
an excellent opportunity to save time and money, bringing 
down the cost.
67 kDa laminin receptor (67LR) overexpression 
correlates with an enhanced invasive and metastatic 
potential in many human tumors [22–24] recommending 
the receptor as a new promising target for cancer drug 
discovery [25]. This is supported by in vivo studies 
showing that 67LR downregulation by antisense RNA 
reduces tumor cell proliferation and tumour formation 
[46]. Our group recently demonstrated that, upon LM 
binding, 67LR association with the anti-apoptotic protein 
PED/PEA-15 activates a signal transduction pathway, 
leading to cell proliferation and resistance to apoptosis 
[28]; indeed, siRNA mediated 67LR downregulation 
reduces cell viability by inducing apoptosis [27].
However, the main function of 67LR is to enhance 
tumor cell adhesion to the LM of basement membranes 
and cell migration, two crucial events in the metastasis 
cascade [20, 21]. Thus, inhibiting 67LR binding to LM 
could be a feasible approach to block metastatic cancer 
cell spread. Recently, several studies have shown that anti-
37LRP/67LR specific antibodies significantly reduce the 
Figure 6: Refinement of lead 67LR inhibitor NSC47924. A. LR-293 cells were plated in LM-coated wells in the presence of the 
selected molecules, dissolved in DMSO at a concentration of 20 μM, DMSO was used as negative control (■). The attached cells were 
stained and the absorbance at 540 nm was measured. The values represent the mean ± SD of three experiments performed in triplicate. (*) p 
< 0.05, as determined by the Student’s t test. Among the 19 small molecules tested, only eight compounds were able to inhibit LR-293 cell 
binding to LM and are shown in figure. B. LR-293 cell adhesion to LM (■) and FN (■), in the presence of 20 μM of inhibitory molecules or 
DMSO, as a negative control. The attached cells were stained and the absorbance at 540 nm was measured. The values represent the mean 
± SD of three experiments performed in triplicate. (*) p < 0.05, as determined by the Student’s t test. Only four compounds specifically 
decreased LR-293 cell binding to LM, without affecting cell adherence to FN and are shown in figure. C. r37LRP was placed for 1 hour at 
37°C on LM-coated wells in the presence of NSC47924 and selected analogs at a concentration of 50 μM; DMSO (■), was used as a vehicle 
control. Bound r37LRP was revealed by anti-His-HRP and OPD staining; the absorbance at 490 nm was measured. r37LRP binding to 
BSA-coated wells was subtracted to obtain specific binding. Values represent the mean ± SD of three experiments carried out in triplicate; 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001), as determined by the Student’s t test.
Oncotarget18126www.impactjournals.com/oncotarget
Table 2: Experimentally Determined IC
50
 Values and Properties Predicted by QikProp of the four 
NSC47924 analogs selectively inhibiting LM binding
Cpd Structure NCI 
number
MWa QP  
log Pb
QP  
log Sc
QP  
P
Caco
d
QP  
log 
Khsae
IC
50
 
(μM)
50
 
47923 263.3 4.0 –4.4 2999 0.453 1.9
52
 
48478 283.8 4.5 –5.0 3491 0.510 1.8
60
 
48869 405.5 6.0 –5.7 4484 1.032 4.0
61
 
48861 419.5 6.3 –6.5 3026 1.236 3.4
aMW, range 95% of drugs (130/725).
bPredicted octanol/water log P, range 95% of drugs (–2/6.5).
cPredicted aqueous solubility, S, in mol/L, range 95% of drugs (–6.5/0.5).
dPredicted Caco-2 cell permeability in nm/s, range 95% of drugs (<25 poor, >500 great).
ePredicted binding to human serum albumin, range 95% of drugs (–1.5/1.5).
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invasive potential of HT1080 fibrosarcoma, lung, cervical, 
colon, prostate, breast and oesophageal cancer cells [30, 
43, 47], thus indicating that 67LR plays a critical role 
in tumor invasion and metastasis through its interaction 
with LM. Furthermore, 67LR interaction with LM might 
also be involved in angiogenesis [48] and recent findings 
suggest that the same anti-37LRP/67LR antibody is also 
able to block angiogenesis [29].
Thus, the main goal of our study was to identify 
small molecules able to inhibit 67LR interaction with 
LM. In our search for active compounds, we reviewed 
biological and biochemical data to identify a significant 
67LR binding site for LM to target. We focused on the 
37LRP-derived “peptide G” sequence (residues 161–180, 
IPCNNKGAHSVGLMWWMLAR) that binds LM with 
high affinity (Kd = 51.8 nM) [11, 15, 17], elutes 67LR from 
LM affinity chromatography columns [17], and mediates 
many functional effect linked to tumor progression, such 
as increased cell adhesion and migration to exposed ECM 
[18], increased tumor cell adhesion to endothelial cells 
and metastasis formation [15] and release of motility 
fragments from LM [19].
Interestingly, the mature 67LR originates from a 
ribosomal protein that acquired the LM binding function 
during evolution. Indeed, both human 37LRP and the p40 
ribosomal protein are encoded by the same gene [9, 10]. 
Sequence conservation of 37LRP/p40 genes across species 
has been demonstrated, with evolution of the C-terminal 
tail, where is located the LM binding function, convergent 
with vertebrates [35]. Evolutionary studies also showed 
that the acquisition of LM-binding capability is linked to 
the palindromic sequence LMWWML contained within 
peptide G, which appeared during evolution concomitantly 
with LM or LM-like molecules. This consistent with the 
observation that two consecutive tryptophan residues are 
often associated with protein-protein interaction [49].
The fact that specific amino acid/s could be 
responsible for the functionality of the complex between 
67LR and LM increased the possibility that a small 
molecule could exert a disrupting effect. Although an 
antibody and a peptide could also be able to target such 
interaction, we believe that a small molecule with the same 
activity would be preferable. Since disruption of LM/67LR 
interaction should block tumor cell invasion rather than 
cause cell death, to be an effective treatment, the drug 
would have to be used chronically in patients suspected to 
have overt disseminated or residual disease. A successful 
outcome implies prolonged treatments and thus the need for 
a drug with oral availability and high index of specificity for 
cancer cells. Because the library was selected on the basis 
of Lipinski’s rule for drug-like properties [50], and because 
of the target, which is an interaction that takes place when 
Figure 7: Predicted binding modes to 37LRP for NSC47923 (A. cyan), NSC48861 (B. white), NSC48869 (C. magenta) 
and NSC48478 (D. orange). Critical 37LRP binding residues are shown (yellow, carbon; red, oxygen; blue, nitrogen), while the 
palindromic key residues are displayed in blue sticks. H-bonds interactions are shown with dashed black lines.
Oncotarget18128www.impactjournals.com/oncotarget
67LR is over-expressed, a condition of malignant tumors, 
those two requirement should be satisfied.
The crystal structure of 37LRP reveals that the 
surface loop of residues 187–205 completely covers 
peptide G, making it inaccessible. Thus, to expose the 
palindromic sequence, we truncated the surface loop of 
37LRP and intercepted a hydrophobic cavity in close 
proximity of the palindromic residue W176. This putative 
cavity was chosen for in silico targeting in a SB-VS 
approach, which has already been used to successfully 
identify small molecule inhibitors of urokinase receptor 
(uPAR) [51], Cdc25B dual specificity phosphatases [52] 
and frataxin ubiquitination [53].
This approach led to the identification of a small 
molecule, NSC47924, with 67LR/LM disrupting activity. 
Since, small molecules have a higher likelihood for 
off-target effects (based on non-selectivity) in respect 
to protein-like biologicals [54], we demonstrated that 
NSC47924 reduced adhesion and migration to LM 
as well as Matrigel invasion of 67LR-overexpressing 
cells, without exerting any significant effect in vector-
transfected cell, poorly expressing 67LR.
NSC47924 is expected to reduce cancer cell spread, 
rather than cause acute cancer cell death; however, we 
cannot exclude that NSC47924 can diffuse through the 
cell membrane, or be internalized upon 67LR binding, and 
thus exert also a role on cell proliferation and survival by 
targeting cytosolic, ribosomal and/or nuclear 37LRP.
Indeed, one of the most important advantages of 
small molecules, in respect to monoclonal antibodies, is 
cell membrane permeability. Moreover, the short half-life 
of small molecules may be of considerable clinical benefit 
in tailoring personalized target therapies in cancer, as it is 
emerging in rheumatology [55].
Figure 8: Selected close analogs of NSC47924 block very efficiently cancer cell invasion. A. Highly invasive HT1080 
fibrosarcoma cells (upper panel) and MDAMB231 human breast cancer cells (lower panel) were treated with DMSO, with 10 μM (first 
line) and 5 μM (second line) of compounds NSC47923, NSC48478, NSC48861, NSC48869 and NSC210423, as a negative control, and 
allowed to invade Matrigel, using as chemoattractant cell culture medium supplemented with 10% FBS. Invading cells on the lower side 
of the membranes were fixed, stained and photographed: a representative image is shown. B. Highly invasive HT1080 fibrosarcoma cells 
(upper panel) and MDAMB231 human breast cancer cells (lower panel) were treated with DMSO (■), with 10 μM and 5 μM of compounds 
NSC47923 (■), NSC48478 (■), NSC48861 ( ), NSC48869 ( ), and NSC210423, as a negative control (□), and allowed to invade Matrigel, 
using as chemoattractant cell culture medium supplemented with 10% FBS. Invading cells on the lower side of the membrane were fixed, 
stained and counted and the results were expressed as a percentage of invasion in the absence of chemoattractant. The values are the mean  
± SD of three experiments carried out in triplicate; (*, P < 0.05; **P < 0.01 ), as determined by the Student’s t test. FBS-induced cancer 
cell invasiveness was significantly reduced by compounds NSC47923, NSC48478, NSC48861, NSC48869, at both concentrations tested.
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Hierarchical screening over the full NCI database 
with NSC47924, molecular docking studies and cell 
adhesion experiments identified four NSC47924 related 
compounds, NSC47923, NSC48478, NSC48861 and 
NSC48869, that showed increased 67LR inhibition ability, 
as compared to NSC47924.
In summary, we combined SB-VS experiments 
with in vitro assays and found five active molecules that 
were able to selectively disrupt the 67LR/LM activity 
in a timely and cost-effective fashion. In particular, we 
have identified a specific inhibitor of cell binding to LM, 
NSC47924, which is cell-permeable and selectively target 
67LR-mediated cell adhesion, migration and invasion as 
well as four its close analogs (NSC47923, NSC48478, 
NSC48861 and NSC48869), even more active. This 
specificity, together with its simple chemical structure, 
make this compound class suitable for further development 
of novel therapeutics for the treatment of 67LR-dependent 
human malignancies.
MATERIALS AND METHODS
Computational chemistry
Molecular modeling and graphics manipulations 
were performed using Maestro (Maestro, version 9.9, 
Schrödinger, LLC) and Pymol [56] software packages 
running on a E4 Computer Engineering E1080 
workstation provided of a Intel Core i7–930 Quad-Core 
processor.
Protein preparation
The X-ray coordinates of the 37LRP fragment 
(PDB code 3BCH) [31] were extracted from the Protein 
Data Bank [57]. The structure was then prepared using the 
Protein Preparation Wizard of the Schrödinger graphical 
interface Maestro. X-ray water molecules and surface loop 
domain (residues 187–205) were removed during protein 
preparation, the last step of which was energy minimization 
of the entire structure. The minimization was terminated 
when the root mean square deviation (rmsd) of the heavy 
atoms in the energy minimized structure relative to the 
starting (X-ray) coordinates exceeded 0.3 Å.
Ligand preparation and filtering
3D structures of NCI Diversity Set (1, 990 
compounds) were extracted by the web site http://
dtp.nci.nih.gov/branches/dscb/repo_open.html/ and 
prepared using LigPrep’s ligand preparation protocol 
(LigPrep, version 3.1, Schrödinger, LLC). So, about 
2, 560 structures including stereoisomers, tautomers, 
and ionization states were ready to be submitted to the 
subsequent docking runs.
SB-VS protocol
The Glide v6.4 (Glide, version 6.4, Schrödinger, 
LLC) [37] VS application in Schrödinger Small-Molecule 
Drug Discovery Suite was used to screen the compound 
library using two levels of docking precision. In the first 
step, Glide was run in Standard Precision (SP) mode. The 
10% of the top-scoring ligands (188 compounds) were kept 
and redocked using the Glide Extra Precision (XP) mode, 
which incorporates a more accurate, finer-grained docking 
algorithm, designed to eliminate false positives that survive 
the SP stage. After visual inspection of the top ranked 
compounds, 46 hits were chosen for biological evaluation. 
The grid for docking studies was chosen sufficiently 
large to enclose all residues involved in the palindromic 
sequence of peptide G (LMWWML) within a cubic box of 
dimensions 40 Å × 40 Å × 40 Å. The enclosing box was 
centered on the palindromic sequence setting the bounding 
box with the sizes of 14 Å × 14 Å × 14 Å. A van der Waals 
radius scaling factor of 0.80 for atoms with a partial atomic 
charge (absolute value) less than 0.15 was used in order 
to soften the potential for nonpolar parts of the receptor. 
Compounds identified by SB-VS were flexibly docked 
using the same protein grid prepared for SB-VS protocol. 
Ten poses were collected for each ligand and ranked 
according to predicted Glide XP score.
Hierarchical similarity search
An online search utility provided by the NCI 
(http://129.43.27.140/ncidb2/) was used to search the 
entire NCI database for compounds similar to NSC 47924. 
Two methods were used to judge compound similarity: 
search on the basis of substructure by SMILES string 
(http://daylight.com) and/or similarity by Tanimoto 
coefficient, [58] with a cutoff of 0.85 [59]. From these 
searches, selected compound structures were docked to 
the putative LM binding pocket and ranked according to 
predicted Glide XP score. Compounds with the lowest 
scoring value were requested and assayed for effect on 
cell adhesion inhibition.
Chemical inhibitors
All compounds identified by SB-VS were obtained 
from the NCI/DTP Open Chemical Repository (http://dtp.
cancer.gov), dissolved in dimethyl sulfoxide (DMSO) and 
stored at –20°C, at a concentration of 0.01 M.
Epitope tagging of the 37LRP for eukaryotic cell 
transfection
The 37LRP cDNA was fused at the carboxy 
terminus with a sequence coding for both a T7 tag 
and a 6xHis tag, by a two step procedure. First, the 
37LRP coding sequence was PCR amplified from 
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plasmid pPLR1.1 [8], kindly provided from Dr. M.E. 
Sobel, (Bethesda, MD), using oligonucleotides PR11 
(GATCCCATTGATGTCCCCAGCCCTTGACGT) and 
PR12 (GATCCCATGGACCACTCAGTGGTGGCT) 
as 5′ and 3′ primers, respectively. The product was then 
cloned in frame into the Nco I site of the pTRcHisB 
vector (Invitrogen, Carlsbad, CA, USA), upstream the 
T7-tag and His-tag sequences. Second, the chimeric 
sequence was PCR amplified using oligonucleotides 
PR10 (GATCAAGCTTATGTCCGGAGCCCTTGACG) 
and PR5 (AGCTTCTAGATCAGAGCTCGGATCCTTA-
TCGTC) as 5′ and 3′ primers, respectively. The product 
was cloned into the Hind III and Xba I sites of pcDNA3 
eukaryotic vector (Invitrogen). The resulting plasmid was 
named pPLR2.5.
Cell cultures and transfections
The human embryonic kidney cell line HEK-293 
(ATCC Certified from LGC Standards, Milan, Italy) was 
grown in Dulbecco’s modified Eagle’s medium (DMEM) 
(GIBCO, Gaithersburg, MD, USA) supplemented with 
10% fetal bovine serum (FBS).
5 × 106 HEK-293 cells, cultured overnight in 100 
mm tissue culture dishes, were stably transfected with 10 
μg of pPLR2.5, or pcDNA3 and 60 μl of LipofectAMINE 
(Invitrogen) for 5 h at 37°C (5% CO2). Transfected cells, 
named LR-293 and V-293 respectively, were selected by 
Geneticin (GIBCO) at 1.5 mg/ml, pooled, and cultured in 
the presence of 0.5 mg/ml Geneticin.
67LR highly expressing HT1080 fibrosarcoma [30] 
and MDAMB231 breast cancer cell lines [43] were grown 
in DMEM supplemented with 10% FBS.
Production of recombinant 37LRP and  
anti-67LR antibodies
A recombinant polypeptide was made in bacteria for 
production of anti-37LRP/67LR antibodies, as described [23].
Flow cytometry
Flow cytometric analysis of cell surface molecules 
was performed as previously described [59].
Western blot
Cells were lysed in PBS (0.08 M NaCl, 0.002 
M KCl, 0.0115 M Na2HPO4, 0.002 M KH2PO4, pH 
7.2) containing 1% Triton X-100, in the presence of a 
protease inhibitor cocktail containing AEBSF, Aprotinin, 
Bestatin, E-64, Leupeptin and Pepstatin A (Sigma-
Aldrich, St. Louis, MO, USA) and a phosphatase inhibitor 
cocktail containing microcystin LR, cantharidin, and 
bromotetramisole (Sigma-Aldrich). Protein concentration 
of lysates was determined using a colorimetric assay 
(Biorad, Richmond, CA, USA). Equal amounts of protein 
were subjected to SDS-polyacrylamide gel electrophoresis, 
transferred to poly-vinyl difluoride (PVDF) filters 
(Millipore, Windsor, MA, USA), then subjected to 
Western blot with a polyclonal anti-37LRP/67LR antibody 
or with non-immune immunoglobulins (Igs) (Jackson 
ImmunoResearch, Suffolk, England), as decribed [23, 60].
Cell adhesion assay
The adhesion assays were carried out on 96-well 
flat-bottomed plates (Nunc, Roskilde, Denmark) coated 
with 1 μg of laminin (LM) (Becton Dickinson Biosciences, 
Franklin Lakes, NJ, USA), fibronectin (FN) (Roche, 
Indianapolis, USA), vitronectin (VN) (Becton Dickinson 
Biosciences, Franklin Lakes, NJ, USA) or with 100 μl 
of heat-denatured 1% Bovine serum albumin (BSA) in 
PBS, as a negative control, as described [23, 28, 60, 61]. 
A binding curve and Kd were generated for compounds 
using GraphPad Prism software.
Cell migration and invasion assays
Cell migration assays were performed in Boyden 
chambers using 8 μm pore size polyvinylpyrrolidone 
(PVPF)-free chemotaxis filters (Wathman Int., Kent, UK), 
coated with 50 μg/ml collagen, as an adhesion substrate. 
V-293 and LR-293 cells (2 × 105) were plated in the upper 
chamber in DMEM 0.1% BSA containing the selected 
small molecules or DMSO, as a vehicle control. DMEM 
0.1% BSA alone or containing 50 μg/ml LM was added in 
the lower chamber and the cells were allowed to migrate 
for 4 h at 37°C, 5% CO
2
.
For the invasion assay, filters were coated with 
50 μg/ml MatrigelTM (BD Biosciences, San Jose, CA) 
and incubated for 30 min at 37°C for gelling. 2 × 105 
cells, plated in the upper chamber in DMEM 0.1% BSA 
containing the selected small molecules or DMSO, 
were allowed to migrate toward DMEM medium 
supplemented with 10% FCS, or toward DMEM medium 
supplemented with 0.1% BSA, as a control, for 18 h at 
37°C, 5% CO
2
.
At the end of both experiments, cells on the lower 
surface of the filter were fixed in ethanol, stained with 
hematoxylin, and counted at 200× magnification (10 
random fields/filter). Cell migration and invasion were 
expressed as a percent increase over the control.
Binding of soluble r37LRP to immobilized LM 
and YIGSR peptide
High binding plates with 96 flat-bottomed wells 
(Corning, Amsterdam, ND) were coated with 1 μg/well 
of LM diluted in PBS, or BSA as a negative control, and 
incubated at 4°C overnight. After a wash in PBS, residual 
binding sites were blocked for 1 h at 37°C with 200 μl of 
blocking buffer (2% FCS, 1 mg/ml BSA, in PBS). Wells 
were incubated with increasing concentration of r37LRP 
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(diluted in PBS, 1 mg/ml BSA), which contained a 6 × 
His-tag, for 1 h at 37°C. Each well was washed three times 
with wash buffer (0.5% Tween in PBS). Penta-His HRP 
conjugate (1:500) (Qiagen) was added for 2 h at room 
temperature. After washing, substrate solution was added 
and absorbance was detected at 490 nm on an ELISA 
plate reader (Bio-Rad). Binding affinity was determined 
by subtracting background absorbance (BSA wells). A 
binding curve and Kd were generated for r37LRP using 
GraphPad Prism software. The Kd was calculated using 
a one-site binding hyperbola and the equation Y = B
max
 × 
X/(Kd+X).
For inhibition experiments, wells precoated with 
1 μg LM or 100 μg peptide YIGSR-amide (Polypeptide 
group, Strasburg) were incubated with 2 μg r37LRP, 
alone or in the presence of different concentrations 
of NSC47924. Washings, detection and analysis were 
performed as above described.
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